BiotechTube
Mirai Bio

Mirai Bio

San Diego, United States· Est.
miraibio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $3M

Overview

Mirai Bio is a private, pre-revenue platform company founded in 2020, positioning itself as the biotech industry's first open end-to-end platform for genetic medicines. Its core technology integrates generative AI design, high-throughput in vivo multiplexing via a unique barcoding approach, and co-optimization of design, delivery, and manufacturing. The company's business model is based on partnering with innovators across genome engineering, tRNA, mRNA, and DNA therapies to co-create and accelerate their programs from concept to clinic.

AI / Machine LearningDrug Delivery

Technology Platform

An open, end-to-end AI/ML-driven platform for genetic medicine design, development, and manufacturing. It integrates generative AI for cargo/vehicle design, high-throughput in vivo multiplexing via barcoding, and co-optimization loops for delivery and manufacturability.

Funding History

1
Total raised:$3M
Seed$3M

Opportunities

The massive and growing genetic medicine market is constrained by delivery challenges, creating a high demand for enabling platforms.
Mirai's open partnership model allows it to capture value across multiple therapeutic areas and modalities without bearing the full cost and risk of drug development.
Success with initial partners can create a powerful network effect, attracting more clients and generating valuable proprietary data to further refine its AI models.

Risk Factors

The platform's capabilities are unproven at scale, and failure to consistently deliver superior results for partners would be existential.
The company faces significant competition from both internal biotech efforts and other AI/platform companies.
As a pre-revenue private company, it is highly dependent on investor funding and securing partnership deals to sustain operations.

Competitive Landscape

Mirai competes with other AI-driven drug discovery platforms (e.g., Recursion, Exscientia) applied to biologics, as well as specialized LNP and delivery technology companies (e.g., Acuitas, Genevant Sciences). Its unique combination of generative AI, high-throughput in vivo testing, and a focus on end-to-end co-optimization for genetic medicines is its key differentiator in a crowded but high-potential space.

More companies in United States →